Status:
RECRUITING
Prognostic Prediction Model of Patients With AcUte Stroke undeRgoing EndOvascular TheRApy (AURORA)
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
18-100 years
Brief Summary
Stroke is the leading cause of disability-adjusted life years (DALYs) in China, imposing a heavy burden on society and families. Endovascular therapy (EVT) has opened the 2.0 era of acute ischemic str...
Eligibility Criteria
Inclusion
- Age ≥18 years;
- NIHSS score ≥4;
- Image-confirmed (CTA/MRA/DSA) intracranial large artery occlusion;
- ASPECT (anterior circulation) or PC-ASPECT (posterior circulation) score ≥3;
- Endovascular treatment including arterial thrombolysis, mechanical thrombolysis, and angioplasty (onset to puncture time is recommended to be less than 8 hours for anterior circulation and less than 12 hours for posterior circulation; those exceeding the time window will be determined by the neurointerventionalist through imaging assessment);
- Signed informed consent by the patient or legal representative
Exclusion
- Pre-stroke mRS score \>2;
- Intracranial bleeding disorders: cerebral hemorrhage, subarachnoid hemorrhage, etc.;
- presence of coagulation disorders, history of systemic bleeding, history of thrombocytopenia or neutropenia;
- Renal insufficiency with elevated blood creatinine (greater than 2 times the upper limit of normal);
- Presence of severe cardiopulmonary disease that, in the opinion of the investigator, makes participation in this study unsuitable; patients with a life expectancy of less than 3 months or otherwise unable to complete this study;
- Contraindication to DSA examination, severe contrast allergy or absolute contraindication to iodine contrast; women of childbearing age who have a negative pregnancy test but refuse to use effective contraception, are pregnant or breast feeding;
- Those who are unable to complete the study due to psychiatric disorders, cognitive or mood disorders;
- Other patients who, in the opinion of the investigator, are not suitable for enrollment in the study (specify reason).
Key Trial Info
Start Date :
February 23 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
949 Patients enrolled
Trial Details
Trial ID
NCT06009315
Start Date
February 23 2024
End Date
December 31 2026
Last Update
August 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100070